Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Effect of Complex Weight-Reducing Interventions on Rhythm Control in Obese Individuals with Atrial Fibrillation Following Catheter Ablation: A Study Protocol

K. Štolbová, P. Novodvorský, I. Jakubíková, I. Dvořáková, M. Mráz, D. Wichterle, J. Kautzner, M. Haluzík

. 2021 ; 38 (4) : 2007-2016. [pub] 20210312

Jazyk angličtina Země Spojené státy americké

Typ dokumentu protokol klinické studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21018880

INTRODUCTION: Obesity and atrial fibrillation (AF) pose a significant burden on healthcare systems worldwide. Reduction of body weight has been documented to reduce the risk of AF. Little is known about the effect of different weight-reducing interventions including bariatric surgery in obese individuals on the risk of arrhythmia recurrence following catheter ablation (CA) for AF, and about the pathophysiological mechanisms linking these two conditions. METHODS: The Effect of complex weigHt-reducing interventiOns on rhythm control in oBese subjects wITh Atrial Fibrillation (HOBIT-AF) is a single-blinded, parallel-group randomised controlled trial with 18-month follow-up to assess the effect of complex weight-reducing interventions supported by the use of smart technologies and bariatric surgery on the arrhythmia burden in obese individuals following CA for AF. One hundred and sixty individuals (age 18-70 years, body mass index ≥ 30 kg/m2) will be randomised in a 1:1 fashion to undergo a structured weight reduction programme and sleeve gastrectomy (when indicated and preferred by the patient) aiming to achieve greater than 10% weight reduction from baseline (intervention group) or standard post-ablation medical care (control group). Two-week continuous ECG monitoring will be used 3 and 18 months after CA to assess the arrhythmia burden. Other investigations will include transthoracic echocardiography with quantification of epicardial adipose tissue, and markers of low-grade inflammation and circulating adipokines. PLANNED OUTCOMES: The main objective is to assess the effect of complex weight-reducing interventions on the arrhythmia burden and quality of life. Subgroup analyses to identify patient subgroups preferentially benefiting from weight loss related to a decrease in arrhythmia burden will be performed. Exploratory objectives will include investigation of potential mechanisms linking weight reduction with amelioration of arrhythmia burden such as changes in markers of low-grade inflammation, circulating adipokines, cytokines, monocytes or reduction of epicardial adipose tissue volume. TRIAL REGISTRATION: NCT04560387.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018880
003      
CZ-PrNML
005      
20220815125731.0
007      
ta
008      
210728s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12325-021-01667-0 $2 doi
035    __
$a (PubMed)33710588
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Štolbová, Kristýna $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic
245    10
$a Effect of Complex Weight-Reducing Interventions on Rhythm Control in Obese Individuals with Atrial Fibrillation Following Catheter Ablation: A Study Protocol / $c K. Štolbová, P. Novodvorský, I. Jakubíková, I. Dvořáková, M. Mráz, D. Wichterle, J. Kautzner, M. Haluzík
520    9_
$a INTRODUCTION: Obesity and atrial fibrillation (AF) pose a significant burden on healthcare systems worldwide. Reduction of body weight has been documented to reduce the risk of AF. Little is known about the effect of different weight-reducing interventions including bariatric surgery in obese individuals on the risk of arrhythmia recurrence following catheter ablation (CA) for AF, and about the pathophysiological mechanisms linking these two conditions. METHODS: The Effect of complex weigHt-reducing interventiOns on rhythm control in oBese subjects wITh Atrial Fibrillation (HOBIT-AF) is a single-blinded, parallel-group randomised controlled trial with 18-month follow-up to assess the effect of complex weight-reducing interventions supported by the use of smart technologies and bariatric surgery on the arrhythmia burden in obese individuals following CA for AF. One hundred and sixty individuals (age 18-70 years, body mass index ≥ 30 kg/m2) will be randomised in a 1:1 fashion to undergo a structured weight reduction programme and sleeve gastrectomy (when indicated and preferred by the patient) aiming to achieve greater than 10% weight reduction from baseline (intervention group) or standard post-ablation medical care (control group). Two-week continuous ECG monitoring will be used 3 and 18 months after CA to assess the arrhythmia burden. Other investigations will include transthoracic echocardiography with quantification of epicardial adipose tissue, and markers of low-grade inflammation and circulating adipokines. PLANNED OUTCOMES: The main objective is to assess the effect of complex weight-reducing interventions on the arrhythmia burden and quality of life. Subgroup analyses to identify patient subgroups preferentially benefiting from weight loss related to a decrease in arrhythmia burden will be performed. Exploratory objectives will include investigation of potential mechanisms linking weight reduction with amelioration of arrhythmia burden such as changes in markers of low-grade inflammation, circulating adipokines, cytokines, monocytes or reduction of epicardial adipose tissue volume. TRIAL REGISTRATION: NCT04560387.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    12
$a fibrilace síní $x komplikace $x chirurgie $7 D001281
650    12
$a katetrizační ablace $7 D017115
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a obezita $x komplikace $x chirurgie $7 D009765
650    _2
$a kvalita života $7 D011788
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a recidiva $7 D012008
650    _2
$a výsledek terapie $7 D016896
650    _2
$a hmotnostní úbytek $7 D015431
650    _2
$a mladý dospělý $7 D055815
655    _2
$a protokol klinické studie $7 D000078325
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Novodvorský, Peter $u Diabetes Centre, Institute for Clinical and Experimental Medicine (IKEM), Vídeňská 1958, 140 21, Prague 4, Czech Republic $u Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK $7 xx0275745
700    1_
$a Jakubíková, Iva $u Diabetes Centre, Institute for Clinical and Experimental Medicine (IKEM), Vídeňská 1958, 140 21, Prague 4, Czech Republic
700    1_
$a Dvořáková, Iveta $u Centre for Experimental Medicine, IKEM, Prague, Czech Republic
700    1_
$a Mráz, Miloš $u Diabetes Centre, Institute for Clinical and Experimental Medicine (IKEM), Vídeňská 1958, 140 21, Prague 4, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Wichterle, Dan $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Kautzner, Josef $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Haluzík, Martin $u Diabetes Centre, Institute for Clinical and Experimental Medicine (IKEM), Vídeňská 1958, 140 21, Prague 4, Czech Republic. halm@ikem.cz $u First Faculty of Medicine, Charles University, Prague, Czech Republic. halm@ikem.cz
773    0_
$w MED00179771 $t Advances in therapy $x 1865-8652 $g Roč. 38, č. 4 (2021), s. 2007-2016
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33710588 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20220815125729 $b ABA008
999    __
$a ok $b bmc $g 1689845 $s 1139326
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 38 $c 4 $d 2007-2016 $e 20210312 $i 1865-8652 $m Advances in therapy $n Adv Ther $x MED00179771
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace